Elite Pharmaceuticals INC /NV/ Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OQB
Elite Pharmaceuticals' EVP of Operations, Douglas Plassche, exercised 2.5 million stock options at $0.03 per share, increasing his direct beneficial ownership to 6 million shares.
OQB
Form 4: ELTP EVP Sells 800,000 Shares
Elite Pharmaceuticals EVP Operations, Douglas Plassche, sold 800,000 shares of common stock at $0.624 per share.
OQB
Elite Pharmaceuticals' EVP Operations, Doug Plassche, reported selling 500,000 shares and exercising 2.5 million stock options, increasing direct common stock ownership.
OQB
Elite Pharmaceuticals' Chief Commercial Officer, Kirko Kirkov, has acquired 16,366 shares of common stock, indicating a vote of confidence in the company's future.
OQB
Elite Pharmaceuticals' Executive Vice President of Operations, Douglas Plassche, reported the sale of 200,000 stock options at $0.579 per share, with a transaction date listed as July 8, 2025.
OQB
Douglas Plassche, Executive Vice President of Operations at Elite Pharmaceuticals Inc., exercised 2.5 million stock options at $0.03 per share, increasing his direct beneficial ownership of common stock.
OQB
Douglas Plassche, SVP of Operations at Elite Pharmaceuticals, sold 800,000 shares on October 23, 2024, and 333,932 shares on October 24, 2024.
OQB
Nasrat A. Hakim, CEO of Elite Pharmaceuticals, acquired 49,534,368 shares of common stock to settle compensation owed under his employment agreement.
OQB
Nasrat Hakim, CEO of Elite Pharmaceuticals, files an amended Form 4 to correct previously reported direct holdings of common stock.